All In Biotech

Drug Trial Radar · NCT07716865

Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)

Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

15

Actual

Start

Apr 3, 2024

Primary completion

Dec 29, 2026

Study completion Jan 31, 2027

Sponsor

Lead sponsor
Arctic TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study aims to measure safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in Subjects with Hereditary Cystatin C Amyloid Angiopathy (HCCAA). In the study participants receive increasing dose or active treatment (250 mg vs 500mg vs 750 mg) or matched placebo in the form of tablets BID.

Conditions

  • Hereditary Cystatin C Amyloid Angiopathy (HCCAA)
  • Hemorrhage Brain
  • Hemorrhage Cerebral

Interventions

  • NACADrug

    250 mg tablets BID, increasing dosage from 250 mg BID to 750 mg BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse EventsTime frame: Through study completion, up to 24 months
  2. Frequency of cerebral bleeding eventsTime frame: Through study completion, up to 24 months
  3. Safety labs results within normal rangeTime frame: Through study completion, up to 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Landspitali University Hospital

    Reykjavik, Iceland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.